Brady Lundin

  • Graduate Student

Creating and utilizing neural tissue engineering platforms for the study of clinical disease.

Human Nature Screening

The the MS Biotechnology program at UW and the Wisconsin Institute for Discovery are partnering to screen the documentary film “Human Nature”, an exploration of gene editing and its implications both biological and ethical.

Chenglong (Belong) Yu

  • Visiting Scholar

Focusing on the researches of small-diameter vascular grafts and rapid endothelialization

Huaguang Yang

  • Visiting Scholar

Advance UHMWPE melt processing technologies, such as injection molding, extrusion and compression

Xiuxiu Wang

  • Postdoctoral Associate

Research interests focus on design of multi-functional nanocarriers for targeted drug delivery

Tiny Capsules Packed with Gene-Editing Tools Offer Alternative to Viral Delivery of Gene Therapy

An interdisciplinary pair of WID researchers has developed a new nanocapsule delivery method for delivering the CRISPR-Cas9 gene editing tool. The new system could be used for many types of gene therapies.

Shivani Saxena

  • Graduate Student

Engineering cells and organism via genome editing and studying the delivery method for CRISPR/Cas9

Xingxing Shi

Xingxing Shi

  • Visiting Scholar

Multifunctional polymer nanocomposites for various applications

Yi Zhao

Yu Zhao

  • Postdoctoral Associate

Drug delivery nanoparticles for vascular diseases.

Min Zhu

MIn Zhu

  • Graduate Student

Nanoparticles for delivery of therapeutic agents and with gene-editing

Randolph Ashton Continues Research into Causes of Lou Gehrig’s Disease

In August 2017, Randolph Ashton received almost $800,000 from the National Institute of Neurological Disorders and Stroke, part of NIH, to continue a five-year research study of Lou Gehrig’s disease (amyotrophic lateral sclerosis, or ALS), after successfully completing its first phase.

UW-Madison to be Partner in Center for Cell Manufacturing Technologies

The National Science Foundation has awarded nearly $20 million to a consortium of universities to support a new engineering research center that will develop transformative tools and technologies for the consistent, scalable, and low-cost production of high-quality living therapeutic cells. Several WID investigators are collaborators on the project.

Nisakorn Yodsanit

Nisakorn Yodsanit

  • Graduate Student

Nanomedicine or nanomaterials for biomedical applications.